νλΌμ‘°μ
νλΌμ‘°μ μ κ³ λλ‘ μ νμ μΈ **μν-1 μλλ λ λ¦° μμ©μ²΄ μ°¨λ¨μ **(κ΅κ°μ κ²½ μ΅μ μ )μ λλ€. μμνμμλ κ³Όκ±° μΈνμ± μ¬λΆμ (CHF) λ° μ μ μ± λλ νλλ§₯ κ³ νμμ 보쑰 μΉλ£λ₯Ό μν νκ΄ νμ₯μ (μ λΆν λ° νλΆν λμ κ°μ)λ‘ μ¬μ©λμμΌλ, νλ μμνμμμ μ£Όλ μ©λλ **νλΆ μλ‘ μ§νμ κ΄λ¦¬**μ λλ€. **μμ μμ :** * **μλ μ΄μ:** νλΌμ‘°μ μ λ΄μλ κ΄μ½κ·Όμ ννκ·Όμ μ΄μμν€λ λ° λ§€μ° ν¨κ³Όμ μ λλ€. κΈ°λ₯μ μλ νμ μΉλ£, νΉν "μλκ° λ§ν κ³ μμ΄"(κ³ μμ΄ νΉλ°μ± λ°©κ΄μΌ/FLUTD) λ° λ°μ¬μ± λ°°λ¨κ·Ό-κ΄μ½κ·Ό νλμ₯μ λ μ 립μ μ§νμ΄ μλ κ°μκ² νμμ μΈ μ½λ¬Όμ λλ€. * **μ¬νκ΄κ³ νΉμ±:** νλλλΌμ§κ³Ό λ¬λ¦¬ νλΌμ‘°μ μ λλ§₯κ³Ό μ λ§₯μ λͺ¨λ νμ₯μν€λ©°, μΌλ°μ μΌλ‘ λ°μ¬μ± λΉλ§₯μ μ λ°νκ±°λ λ λ λΆλΉλ₯Ό μ¦κ°μν€μ§ μμ΅λλ€.
μμ© κΈ°μ : **Prazosin** competitively binds to and blocks **post-synaptic alpha-1 adrenergic receptors**. * **Genitourinary Tract:** Blockade of alpha-1 receptors in the trigone of the bladder and the proximal urethra β **smooth muscle relaxation** β decreased urethral resistance β facilitates micturition and relieves functional obstruction. * **Cardiovascular System:** Blockade of alpha-1 receptors on vascular smooth muscle β **vasodilation** of both arterioles and veins β decreased peripheral vascular resistance (afterload) and decreased venous return (preload) β lowered systemic blood pressure and reduced right atrial pressure.
λλ¬Ό μ’ λ³ μ©λ
- Decrease urethral resistance Β· 0.5 mg (total dose) PO q8h or 0.03 mg/kg IV Β· PO/IV Β· q8h (PO)
- Decrease urethral resistance Β· 0.03 mg/kg IV Β· IV
- Functional urethral obstruction Β· 0.25-0.5 mg/cat (total dose) PO q12-24h Β· PO Β· q12-24h
- Urethral spasm Β· 0.25-1 mg/cat (total dose) PO q8-12h Β· PO Β· q8-12h Β· Initially give for 5-7 days then wean off if possible
- Reduce urethral tone Β· 0.5 mg/cat (total dose) PO once to two times a day Β· PO Β· q12-24h
- Adjunctive treatment of heart failure Β· 1 mg PO three times daily for dogs weighing less than 15 kg; 2 mg three times daily PO for dogs weighing more than 15 kg Β· PO Β· q8h
- Hypertension Β· 1-4 mg (total dose) PO q12-24 hours Β· PO Β· q12-24h
- Hypertension in a large dog Β· 1 mg (total dose) PO q8-12h Β· PO Β· q8-12h
- Decrease urethral resistance Β· 1 mg per 15 kg of body weight PO q8h Β· PO Β· q8h
- Functional urethral obstruction Β· 1 mg/15 kg of body weight PO q8-24h Β· PO Β· q8-24h
- Decrease urethral resistance Β· 1 mg per 15 kg of body weight PO q12-24h Β· PO Β· q12-24h
ν¬μ¬ κ²½λ‘
κΈκΈ°
- Preexisting hypotensive conditions
- Pre-existing hypotension
- Hypovolemia
- Known hypersensitivity to alpha-blockers
μ΄μλ°μ
- Hypotension (including orthostatic hypotension/syncope)
- Lethargy
- Dizziness
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Tachyphylaxis (drug tolerance)
- Hypotension (especially first-dose effect)
- Lethargy / Weakness
- Dizziness / Syncope
- Gastrointestinal upset (vomiting, diarrhea)
- Reflex tachycardia
μ½λ¬Ό μνΈμμ©
- Beta-blocking agents (e.g., propranolol) Β· May enhance the postural hypotensive effects seen after the first dose of prazosin
- Clonidine Β· May decrease prazosin antihypertensive effects
- Sildenafil (and other PDE inhibitors) Β· May increase risk for hypotension
- Verapamil or Nifedipine Β· May cause synergistic hypotensive effects when used concomitantly with prazosin
- Amlodipine Β· Additive hypotensive effects Β· moderate
- ACE Inhibitors (e.g., Benazepril, Enalapril) Β· Increased risk of severe hypotension Β· moderate
- Beta-blockers (e.g., Propranolol) Β· Exacerbation of postural hypotension Β· moderate
- Sildenafil Β· Profound hypotension Β· major
λͺ¨λν°λ§
- Baseline thoracic radiographs
- Mucous membrane color
- Capillary refill time (CRT)
- Arterial blood pressure
- Venous PO2 (if possible)
- Systemic blood pressure
- Heart rate
- Urine output and ease of urination (if used for urethral spasm)
κ³Όμ©λ
Based on ASPCA APCC data (2008-2009): * **Dogs:** Common findings include hyperactivity, tachycardia, hyperthermia, panting, and agitation. * **Cats:** Common findings include tachycardia. **Treatment:** * Evacuate gastric contents and administer activated charcoal using standard precautionary measures if ingestion was recent and cardiovascular status is stable. * Monitor heart rate and blood pressure. * Treat shock using volume expanders and pressor agents if necessary. * Monitor and support renal function.
VetSheet μ½λ¬Ό λ νΌλ°μ€λ λ©΄ν μμ μ λ¬Έκ°λ₯Ό μν μμ μμ¬κ²°μ 보쑰 λꡬμ΄λ©°, μ λ¬Έμ νλ¨μ΄λ μ μ‘°μ¬μ μ΅μ λΌλ²¨μ λμ νμ§ μμ΅λλ€.